Fortress Biotech Inc(FBIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 0.73 | EPS (ttm) | 2.66 | Insider Own | 30.9% | Shs Outstand | 33.3M | Perf Week | -0.52% |
| Market Cap | 0.06B | Forward P/E | - | EPS next Y | -139.22% | Insider Trans | - | Shs Float | 23.0M | Perf Month | -11.06% |
| Enterprise Value | -0.04B | PEG | - | EPS next Q | -0.27 | Inst Own | 22.65% | Short Float | 19.63% | Perf Quarter | -42.39% |
| Income | 0.10B | P/S | 0.94 | EPS this Y | 3742.86% | Inst Trans | 2.93% | Short Ratio | 10.71 | Perf Half Y | -13.84% |
| Sales | 0.07B | P/B | 0.39 | EPS next 5Y | - | ROA | 46.92% | Short Interest | 4.52M | Perf YTD | -47.27% |
| Book/sh | 4.93 | P/C | 0.33 | EPS past 3/5Y | 83.35% 62.98% | ROE | 107.48% | 52W High | -57.4% ($4.53) | Perf Year | -24.9% |
| Cash/sh | 5.89 | P/FCF | 0.54 | Sales past 3/5Y | -5.83% 6.77% | ROIC | 53.19% | 52W Low | 5.46% ($1.83) | Perf 3Y | 8.43% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 401.39% | Gross Margin | 58.88% | Volatility(W/M) | 3.74% 4.12% | Perf 5Y | -96.04% |
| Dividend TTM | - | EV/Sales | -0.54 | Sales Y/Y TTM | 15.46% | Oper. Margin | -42.86% | ATR (14) | 0.09 | Perf 10Y | -94.71% |
| Dividend Ex-Date | - | Quick Ratio | 3.83 | EPS Q/Q | -117.4% | Profit Margin | 150.97% | RSI (14) | 37.25 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.96 | Sales Q/Q | 14.04% | SMA20 | -3.15% ($1.99) | Beta | 1.27 | Target Price | $5 |
| Payout | - | Debt/Eq | 0.32 | Earnings | 2026/8/13 | SMA50 | -18.24% ($2.36) | Rel Volume | 0.37 | Prev Close | $1.87 |
| Employees | 78 | LT Debt/Eq | 0.28 | EPS/Sales Surpr. | 60% 2.28% | SMA200 | -31.45% ($2.82) | Avg Volume(3M) | 0.42M | Price | $1.93 |
| IPO | 2011/11/17 | Option/Short | Yes/Yes | Trades | 761 | Volume | 156,880 | Change | 3.21% |
🧬 Fortress Biotech is a U.S. biopharmaceutical holding company that acquires, develops, and commercializes pharmaceutical and biotechnology products through multiple subsidiaries. It operates a number of subsidiaries across oncology, rare diseases, and dermatology, with a decentralized development structure in which each subsidiary independently manages its own drug pipeline and marketed products.
Over the past 1 year, on the lower side
57% below its 1-year high.
Traded less than usual. That is 37% of its average volume.
FBIO has a sound balance sheet but weak earning power
Of every $100 in sales, $42.86 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +3742.9% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company earning $100 a year, you would pay $73. Peers typically go for $1,456. Compared with its own 3-year average, it is 67% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 22.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #393 of 594 in the industry
Based on market cap of $64M.
CSBR#391 Champions Oncology Inc $67M PER - 
SPRO#392 Spero Therapeutics Inc $66M PER 10.4 FBIO#393 Fortress Biotech Inc $64M PER 0.7 
TENX#393 Tenax Therapeutics Inc $64M PER - 
RNXT#395 RenovoRx Inc $63M PER - 
FAQ
What kind of company is FBIO?
FBIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of FBIO?
The market cap of FBIO is approximately $64M, ranking 4,715 within its sector.
What is the P/E ratio of FBIO?
FBIO has a P/E ratio of approximately 0.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for FBIO?
FBIO has recorded a 52-week high of $4.53 and a low of $1.83.
